BriaCell Therapeutics Corp., a biotechnology company focused on immuno-oncology, is making strides in the development of new cancer therapies. With their lead drug candidate, Bria-IMT, currently in Phase I/IIa clinical trials alongside immunotherapy development candidates retifanlimab, they are moving closer to finding effective cancer treatments. Additionally, BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic tool used to determine patients' HLA types. The company has also formed strategic partnerships with Incyte Corporation and the National Cancer Institute to further its research and development efforts. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BriaCell Therapeutics Corp.'s ticker is BCTX
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at BriaCell Therapeutics Corp.
It is https://briacell.com/
BriaCell Therapeutics Corp. is in the Healthcare sector
BriaCell Therapeutics Corp. is in the Biotechnology industry
The following five companies are BriaCell Therapeutics Corp.'s industry peers: